Ignite Creation Date:
2025-12-25 @ 2:59 AM
Ignite Modification Date:
2025-12-26 @ 1:40 AM
Study NCT ID:
NCT00298233
Status:
COMPLETED
Last Update Posted:
2014-06-06
First Post:
2006-03-01
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Indonesia', 'United Kingdom', 'United States']}, 'conditionBrowseModule': {'meshes': [{'id': 'D007251', 'term': 'Influenza, Human'}, {'id': 'D005585', 'term': 'Influenza in Birds'}, {'id': 'D004417', 'term': 'Dyspnea'}], 'ancestors': [{'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D009976', 'term': 'Orthomyxoviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D001715', 'term': 'Bird Diseases'}, {'id': 'D000820', 'term': 'Animal Diseases'}, {'id': 'D012120', 'term': 'Respiration Disorders'}, {'id': 'D012818', 'term': 'Signs and Symptoms, Respiratory'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D053139', 'term': 'Oseltamivir'}], 'ancestors': [{'id': 'D000081', 'term': 'Acetamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D053138', 'term': 'Cyclohexenes'}, {'id': 'D003510', 'term': 'Cyclohexanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'info@oucru.org', 'phone': '+84 839237954', 'title': 'Dr. Jeremy Farrar', 'organization': 'Oxford University Clinical Research Unit'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Through Day 28 for severe influenza, and Day 180 for avian influenza.', 'description': 'The study recorded only cumulative data (total number of AEs per type, per Arm, but not number of subjects affected per AE type). Therefore data are the number of events and not the number of participants with events.', 'eventGroups': [{'id': 'EG000', 'title': 'Double Dose Oseltamivir', 'description': 'The study recorded only cumulative data (total number of adverse events (AEs) per type, per Arm, but not number of subjects affected per AE type). Therefore data are the number of events and not the number of participants with events.', 'otherNumAtRisk': 165, 'otherNumAffected': 37, 'seriousNumAtRisk': 165, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Standard Dose Oseltamivir', 'description': 'The study recorded only cumulative data (total number of adverse events (AEs) per type, per Arm, but not number of subjects affected per AE type). Therefore data are the number of events and not the number of participants with events.', 'otherNumAtRisk': 161, 'otherNumAffected': 38, 'seriousNumAtRisk': 161, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 9, 'numAffected': 9}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'multi-organ failures', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'acute respiratory distress syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'pneumothorax', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'Thrombocytosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'Septic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}, {'term': 'other', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 11, 'numAffected': 11}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}], 'seriousEvents': [{'term': 'Septic shock', 'notes': 'A participant was admitted to the hospital for suspected pneumonia. Following upper GI bleeding and respiratory failure, diagnosis confirmed as septic shock. Subject eventually stabilized. Unblinding revealed subject was on high dose oseltamivir.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 161, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'WHO ATC'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Proportion of All Participants Negative for Viral RNA on Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '159', 'groupId': 'OG000'}, {'value': '154', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Double Dose Oseltamivir', 'description': 'All participants receiving double dose oseltamivir'}, {'id': 'OG001', 'title': 'Standard Dose Oseltamivir', 'description': 'All participants receiving standard dose oseltamivir'}], 'classes': [{'categories': [{'measurements': [{'value': '115', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.42', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'Significance assessed at the 5% level for a two-sided comparison', 'groupDescription': 'Based on previous studies, assumption was made that 30% of children and 55% of adults treated with standard dose oseltamivir would test negative for virus on day five. This would require a sample size of 242 patients to show a 20% absolute improvement in cessation of viral shedding with 85% power and a two sided α of 0.05. To allow for study withdrawals, the target sample size was set at 300 patients.', 'statisticalMethod': 'conditional univariate logistic regressi', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'analysis stratified by study site', 'testedNonInferiority': False}], 'paramType': 'NUMBER', 'timeFrame': 'After 5 days of treatment', 'description': 'Proportion of all participants with no detectable viral RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in a combined nasal and throat swab sample on day 5.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized patients with RT-PCR proven influenza.'}, {'type': 'SECONDARY', 'title': 'Participants Meeting Criteria for Day 5 Clinical Failure', 'denoms': [{'units': 'Participants', 'counts': [{'value': '161', 'groupId': 'OG000'}, {'value': '158', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Double Dose Oseltamivir', 'description': 'All participants receiving double dose oseltamivir'}, {'id': 'OG001', 'title': 'Standard Dose Oseltamivir', 'description': 'All participants receiving standard dose oseltamivir'}], 'classes': [{'categories': [{'measurements': [{'value': '16', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.54', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'Significance assessed at the 5% level for a two-sided comparison', 'statisticalMethod': 'Mantel Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'NUMBER', 'timeFrame': 'After 5 days of treatment', 'description': 'Proportion of participants that have clinical failure by day 5. Subjects that meet one of the following on Day 5 will be classified as a clinical failure:\n\n* Severe tachypnea (respiratory rate ≥ 30 for ages ≥12 years, rate ≥ 40 for ages 6 to 12 years, rate ≥45 for ages 3 to 6 years, rate ≥ 50 for ages 1 to 3 years)\n* Severe dyspnea (unable to speak full sentences, or use of accessory respiratory muscles)\n* Arterial oxygen saturation ≤92% on room air by trans-cutaneous method\n* Need for mechanical ventilation or intensive care unit (ICU) admission For the purpose of endpoint definition, death prior to or on Day 5 will also be considered a clinical failure at Day 5.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'For the purpose of endpoint definition, death prior to or on Day 5 was also considered as clinical failure on day 5.In the double dose cohort, only 154 subjects completed fives days of drug and 7 died (total 161). In the standard dose cohort only 149 subjects completed 5 days of drug and 9 died (total 158).'}, {'type': 'SECONDARY', 'title': 'In-hospital Mortality Rates', 'denoms': [{'units': 'Participants', 'counts': [{'value': '165', 'groupId': 'OG000'}, {'value': '161', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Double Dose Oseltamivir', 'description': 'All participants receiving double dose oseltamivir'}, {'id': 'OG001', 'title': 'Standard Dose Oseltamivir', 'description': 'All participants receiving standard dose oseltamivir'}], 'classes': [{'categories': [{'measurements': [{'value': '12', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.54', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'Significance assessed at the 5% level for a two-sided comparison', 'statisticalMethod': 'Mantel Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Mantel-Haenszel chi-square stratified by study site', 'testedNonInferiority': False}], 'paramType': 'NUMBER', 'timeFrame': 'After up to 10 days of treatment', 'description': 'Standard therapy with oseltamivir is five days. Those patients with persistent symptoms on day five were continued on the randomized dose for an additional five days and assessments were performed up to day 10.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Median Time (Days) Receipt of Oxygen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '165', 'groupId': 'OG000'}, {'value': '161', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Double Dose Oseltamivir', 'description': 'All participants receiving double dose oseltamivir'}, {'id': 'OG001', 'title': 'Standard Dose Oseltamivir', 'description': 'All participants receiving standard dose oseltamivir'}], 'classes': [{'categories': [{'measurements': [{'value': '3', 'spread': '2-5', 'groupId': 'OG000', 'lowerLimit': '2', 'upperLimit': '5'}, {'value': '3.5', 'spread': '2-7', 'groupId': 'OG001', 'lowerLimit': '2', 'upperLimit': '7'}]}]}], 'analyses': [{'pValue': '0.48', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'Significance assessed at the 5% level for a two-sided comparison', 'statisticalMethod': 'Kruskal-Wallis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEDIAN', 'timeFrame': 'Throughout study, 14 days', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Median Time (Days) in ICU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '165', 'groupId': 'OG000'}, {'value': '161', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Double Dose Oseltamivir', 'description': 'All participants receiving double dose oseltamivir'}, {'id': 'OG001', 'title': 'Standard Dose Oseltamivir', 'description': 'All participants receiving standard dose oseltamivir'}], 'classes': [{'categories': [{'measurements': [{'value': '4.4', 'groupId': 'OG000', 'lowerLimit': '3', 'upperLimit': '6'}, {'value': '5', 'groupId': 'OG001', 'lowerLimit': '2', 'upperLimit': '11'}]}]}], 'analyses': [{'pValue': '0.66', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'Significance assessed at the 5% level for a two-sided comparison', 'statisticalMethod': 'Kruskal-Wallis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEDIAN', 'timeFrame': 'Throughout study, 14 days', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Median Time (Days) on Ventilation', 'denoms': [{'units': 'Participants', 'counts': [{'value': '165', 'groupId': 'OG000'}, {'value': '161', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Double Dose Oseltamivir', 'description': 'All participants receiving double dose oseltamivir'}, {'id': 'OG001', 'title': 'Standard Dose Oseltamivir', 'description': 'All participants receiving standard dose oseltamivir'}], 'classes': [{'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000', 'lowerLimit': '1', 'upperLimit': '16'}, {'value': '5', 'groupId': 'OG001', 'lowerLimit': '2', 'upperLimit': '11'}]}]}], 'analyses': [{'pValue': '0.58', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'Significance assessed at the 5% level for a two-sided comparison', 'statisticalMethod': 'Kruskal-Wallis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEDIAN', 'timeFrame': 'Throughout study, 14 days', 'description': 'Use of mechanical ventilation at any time for subjects with severe influenza and avian influenza.', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Standard Dose Oseltamivir Adult Cohort', 'description': 'All participants \\>= 15 years received standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.'}, {'id': 'FG001', 'title': 'Double Dose Oseltamivir Adult Cohort', 'description': 'All Participants \\>= 15 years received high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.'}, {'id': 'FG002', 'title': 'Standard Dose Oseltamivir Child Cohort', 'description': 'All participants \\<15 years received standard dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.'}, {'id': 'FG003', 'title': 'Double Dose Oseltamivir Child Cohort', 'description': 'All Participants \\<15 years received high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '39'}, {'groupId': 'FG001', 'numSubjects': '41'}, {'groupId': 'FG002', 'numSubjects': '122'}, {'groupId': 'FG003', 'numSubjects': '124'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '39'}, {'groupId': 'FG001', 'numSubjects': '41'}, {'groupId': 'FG002', 'numSubjects': '122'}, {'groupId': 'FG003', 'numSubjects': '124'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '161', 'groupId': 'BG000'}, {'value': '165', 'groupId': 'BG001'}, {'value': '326', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Standarad Dose Oseltamivir', 'description': 'All participants that were randomized and received standard dose oseltamivir'}, {'id': 'BG001', 'title': 'Double Dose Oseltamivir', 'description': 'All participants that were randomized and received doubledose oseltamivir'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'title': 'Child cohort: ≥1 to <15 years', 'categories': [{'measurements': [{'value': '122', 'groupId': 'BG000'}, {'value': '124', 'groupId': 'BG001'}, {'value': '246', 'groupId': 'BG002'}]}]}, {'title': 'Adult cohort: ≥15 years', 'categories': [{'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '41', 'groupId': 'BG001'}, {'value': '80', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '72', 'groupId': 'BG000'}, {'value': '69', 'groupId': 'BG001'}, {'value': '141', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '89', 'groupId': 'BG000'}, {'value': '96', 'groupId': 'BG001'}, {'value': '185', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'All participants that were randomized'}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 326}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2006-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-05', 'completionDateStruct': {'date': '2010-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-05-26', 'studyFirstSubmitDate': '2006-03-01', 'resultsFirstSubmitDate': '2014-01-17', 'studyFirstSubmitQcDate': '2006-02-28', 'lastUpdatePostDateStruct': {'date': '2014-06-06', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2014-04-28', 'studyFirstPostDateStruct': {'date': '2006-03-01', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2014-05-22', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2010-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of All Participants Negative for Viral RNA on Day 5', 'timeFrame': 'After 5 days of treatment', 'description': 'Proportion of all participants with no detectable viral RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in a combined nasal and throat swab sample on day 5.'}], 'secondaryOutcomes': [{'measure': 'Participants Meeting Criteria for Day 5 Clinical Failure', 'timeFrame': 'After 5 days of treatment', 'description': 'Proportion of participants that have clinical failure by day 5. Subjects that meet one of the following on Day 5 will be classified as a clinical failure:\n\n* Severe tachypnea (respiratory rate ≥ 30 for ages ≥12 years, rate ≥ 40 for ages 6 to 12 years, rate ≥45 for ages 3 to 6 years, rate ≥ 50 for ages 1 to 3 years)\n* Severe dyspnea (unable to speak full sentences, or use of accessory respiratory muscles)\n* Arterial oxygen saturation ≤92% on room air by trans-cutaneous method\n* Need for mechanical ventilation or intensive care unit (ICU) admission For the purpose of endpoint definition, death prior to or on Day 5 will also be considered a clinical failure at Day 5.'}, {'measure': 'In-hospital Mortality Rates', 'timeFrame': 'After up to 10 days of treatment', 'description': 'Standard therapy with oseltamivir is five days. Those patients with persistent symptoms on day five were continued on the randomized dose for an additional five days and assessments were performed up to day 10.'}, {'measure': 'Median Time (Days) Receipt of Oxygen', 'timeFrame': 'Throughout study, 14 days'}, {'measure': 'Median Time (Days) in ICU', 'timeFrame': 'Throughout study, 14 days'}, {'measure': 'Median Time (Days) on Ventilation', 'timeFrame': 'Throughout study, 14 days', 'description': 'Use of mechanical ventilation at any time for subjects with severe influenza and avian influenza.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Antibody Response', 'Antiviral Efficacy', 'Bird Flu', 'Severe Respiratory Distress', 'Viral Replication and Shedding'], 'conditions': ['Influenza', 'Avian Influenza', 'Severe Influenza']}, 'referencesModule': {'references': [{'pmid': '8903148', 'type': 'BACKGROUND', 'citation': 'Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis. 1995 Jan-Mar;1(1):7-15. doi: 10.3201/eid0101.950102.'}, {'pmid': '7849585', 'type': 'BACKGROUND', 'citation': 'Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 1994 Oct;3(10):1687-96. doi: 10.1002/pro.5560031007.'}, {'pmid': '15716562', 'type': 'BACKGROUND', 'citation': 'de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, Nguyen BH, Beld M, Le TP, Truong HK, Nguyen VV, Tran TH, Do QH, Farrar J. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005 Feb 17;352(7):686-91. doi: 10.1056/NEJMoa044307.'}, {'pmid': '23723457', 'type': 'RESULT', 'citation': 'South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ. 2013 May 30;346:f3039. doi: 10.1136/bmj.f3039.'}]}, 'descriptionModule': {'briefSummary': 'Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.', 'detailedDescription': 'Two main types of influenza virus--Types A and B--are responsible for the seasonal flu epidemics that occur each year. The influenza A viruses can be broken down into subtypes based on two proteins on the surface of the virus: hemagglutinin (H) and neuraminidase (N). The A subtypes usually found in humans are H1N1, H1N2, and H3N2. Other A subtypes are found primarily in animals. For example, the "avian influenza virus" refers to an influenza A virus that is found chiefly in birds.\n\nAlthough avian influenza does not usually affect humans, increasing numbers of cases of human infection from avian influenza virus H5N1 have been reported in the last several years. Because all influenza viruses have the ability to modify, there is concern that this trend of increasing cases may pose a threat of a future pandemic with a new H5N1 virus that could spread easily from person to person.\n\nThe H5N1 virus that has caused human infection in Asia is resistant to amantadine and rimantadine, two antiviral medications commonly used for treating people with influenza. Another antiviral medication, oseltamivir, is currently used to treat people with uncomplicated human influenza. The purpose of this study is to compare standard-dose oseltamivir and high-does oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza. The study will also attempt to identify how severe human influenza and avian influenza differ in the following factors: clinical manifestation, relationship between antiviral plasma concentrations and viral dynamics, and pathogenesis.\n\nUpon meeting certain screening criteria, participants will be randomly assigned to receive oseltamivir either at a standard-dose level (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) or at a high-dose level (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function). Treatment will continue for 5 days, after which participants who meet clinical failure criteria will continue their assigned treatment for an additional 5 days. It is anticipated that participants will remain hospitalized through the course of treatment. On Day 0, which marks the first day of hospitalization, participants will undergo a medical review, physical examination, blood sampling, nasal swab, throat swab, anal swab, and chest x-ray. An endotracheal aspirate procedure and urine sampling may also be performed. During the hospital stay, most of the above procedures will be repeated regularly, and additional samples of lung fluid, cerebral spinal fluid, and pleural fluid may be obtained. On Day 5 and possibly on Day 10, participants will undergo a follow-up x-ray. If applicable, participants will attend outpatient study visits on Days 10, 14, and 28 for further evaluation; participants with avian influenza will also attend visits on Days 56 and 180.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '1 Year', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* At least one of the following respiratory symptoms: cough, dyspnea, sore throat\n* Evidence of severe influenza or avian influenza, as defined below\n* Severe influenza infection criteria:\n\n 1. Need for hospitalization\n 2. One of the following:\n\n 1. New infiltrate on chest x-ray (or any infiltrate if no prior chest x-ray or not known)\n 2. Severe tachypnea (more information on this criterion can be found in the protocol)\n 3. Severe dyspnea\n 4. Arterial oxygen saturation of 92% or less on room air by trans-cutaneous method\n 3. Positive diagnostic testing for influenza, as defined by either rapid influenza antigen (Ag) positive (A or B) or qualitative reverse transcriptase-polymerase chain reaction (RT-PCR) positive for any influenza\n 4. Illness (defined by onset of fever, respiratory symptoms, or constitutional symptoms) began within 10 days before study enrollment\n* Avian influenza infection criteria:\n\n 1. Nasal wash, nasopharyngeal aspirate, endotracheal aspirate, nasal swab, or throat swab that is RT-PCR positive influenza for H5 influenza\n 2. Illness (defined by onset of fever, respiratory symptoms, or constitutional symptoms) began within 14 days before study enrollment\n\nExclusion Criteria:\n\n* Received more than 72 hours of oseltamivir (six doses) within 14 days\n* Received oseltamivir at higher than standard doses within the last 14 days or during current acute illness, whichever is longer\n* History of allergy or severe intolerance of oseltamivir, as determined by the investigator\n* Alternate explanation for the clinical findings, as determined by the investigator and with the information immediately available\n* Creatine clearance less than 10 ml/minute\n* Pregnant or breastfeeding'}, 'identificationModule': {'nctId': 'NCT00298233', 'briefTitle': 'High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza', 'organization': {'class': 'NIH', 'fullName': 'National Institute of Allergy and Infectious Diseases (NIAID)'}, 'officialTitle': 'High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial', 'orgStudyIdInfo': {'id': 'SEA 001'}, 'secondaryIdInfos': [{'id': 'N01A050042', 'type': 'OTHER_GRANT', 'domain': 'US NIH NIAID Contract'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Standard Dose oseltamivir adult cohort', 'description': 'All participants \\>= 15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.', 'interventionNames': ['Drug: Oseltamivir']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Double Dose oseltamivir Adult cohort', 'description': 'All participants \\>= 15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.', 'interventionNames': ['Drug: Oseltamivir']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Standard Dose Oseltamivir child cohort', 'description': 'All participants \\<15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.', 'interventionNames': ['Drug: Oseltamivir']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Double Dose Oseltamivir child cohort', 'description': 'All Participants \\<15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.', 'interventionNames': ['Drug: Oseltamivir']}], 'interventions': [{'name': 'Oseltamivir', 'type': 'DRUG', 'otherNames': ['Tamiflu'], 'description': 'Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).', 'armGroupLabels': ['Double Dose Oseltamivir child cohort', 'Double Dose oseltamivir Adult cohort', 'Standard Dose Oseltamivir child cohort', 'Standard Dose oseltamivir adult cohort']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Singapore', 'country': 'Singapore', 'facility': 'Changi General Hospital', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'National University Hospital, National University of Singapore', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'Tan Tock Seng Hospital', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Bangkok', 'country': 'Thailand', 'facility': 'Queen Sirikit National Institute of Child Health', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'city': 'Bangkok', 'country': 'Thailand', 'facility': 'Siriraj Hospital Mahidol University', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'city': 'Nonthaburi', 'country': 'Thailand', 'facility': 'Bamrasnaradura Infectious Disease Institute', 'geoPoint': {'lat': 13.86075, 'lon': 100.51477}}, {'city': 'Nonthaburi', 'country': 'Thailand', 'facility': 'Chest Disease Institute', 'geoPoint': {'lat': 13.86075, 'lon': 100.51477}}, {'city': 'Hanoi', 'country': 'Vietnam', 'facility': 'National Hospital of Pediatrics', 'geoPoint': {'lat': 21.0245, 'lon': 105.84117}}, {'city': 'Hanoi', 'country': 'Vietnam', 'facility': 'National Institute fof Infectious and Tropical Diseases', 'geoPoint': {'lat': 21.0245, 'lon': 105.84117}}, {'city': 'Ho Chi Minh City', 'country': 'Vietnam', 'facility': "Children's Hospital #1", 'geoPoint': {'lat': 10.82302, 'lon': 106.62965}}, {'city': 'Ho Chi Minh City', 'country': 'Vietnam', 'facility': 'Hospital for Tropical Diseases', 'geoPoint': {'lat': 10.82302, 'lon': 106.62965}}, {'city': 'Ho Chi Minh City', 'country': 'Vietnam', 'facility': 'Pediatric Hospital #2', 'geoPoint': {'lat': 10.82302, 'lon': 106.62965}}], 'overallOfficials': [{'name': 'Tawee Chotpitayasunohdh, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Queen Sirikit National Institute of Child Health, Bangkok, Thailand'}, {'name': 'Tran Tinh Hien, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'class': 'NIH'}, 'collaborators': [{'name': 'Wellcome Trust', 'class': 'OTHER'}, {'name': 'World Health Organization', 'class': 'OTHER'}, {'name': 'University of Oxford', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Director, Oxford University Clinical Research Unit', 'investigatorFullName': 'Jeremy Farrar', 'investigatorAffiliation': 'Oxford University Clinical Research Unit, Vietnam'}}}}